204 related articles for article (PubMed ID: 15475569)
21. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
25. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
26. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes.
Blanco FJ; Guitian R; Moreno J; de Toro FJ; Galdo F
J Rheumatol; 1999 Jun; 26(6):1366-73. PubMed ID: 10381057
[TBL] [Abstract][Full Text] [Related]
27. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
Galli G; Panzetta G
G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
[TBL] [Abstract][Full Text] [Related]
28. A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2).
Vane JR; Botting RM
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():41-8. PubMed ID: 7537433
[No Abstract] [Full Text] [Related]
29. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
30. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Palackal NT; Lee SH; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2002 Jul; 277(27):24799-808. PubMed ID: 11978787
[TBL] [Abstract][Full Text] [Related]
31. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs.
Smith WL; DeWitt DL
Semin Nephrol; 1995 May; 15(3):179-94. PubMed ID: 7631045
[TBL] [Abstract][Full Text] [Related]
32. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
33. Scientific rationale for specific inhibition of COX-2.
Bolten WW
J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
[TBL] [Abstract][Full Text] [Related]
34. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
35. Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.
Veliça P; Davies NJ; Rocha PP; Schrewe H; Ride JP; Bunce CM
Mol Cancer; 2009 Dec; 8():121. PubMed ID: 20003443
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
37. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.
Brožič P; Turk S; Rižner TL; Gobec S
Curr Med Chem; 2011; 18(17):2554-65. PubMed ID: 21568892
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
[TBL] [Abstract][Full Text] [Related]
40. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.
Jouzeau JY; Terlain B; Abid A; Nédélec E; Netter P
Drugs; 1997 Apr; 53(4):563-82. PubMed ID: 9098660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]